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Previous work has demonstrated that two key melanocyte-specific elements termed the MSEu and MSEi play
critical roles in the expression of the melanocyte-specific tyrosinase-related protein 1 (TRP-1) promoter. Both
the MSEu and MSEi, located at position 2237 and at the initiator, respectively, bind a melanocyte-specific
factor termed MSF but are also recognized by a previously uncharacterized repressor, since mutations affecting
either of these elements result in strong up-regulation of TRP-1 promoter activity in melanoma cells. Here we
demonstrate that repression mediated by the MSEu and MSEi also operates in melanocytes. We also report
that both the MSEu and MSEi are recognized by the brachyury-related transcription factor Tbx2, a member
of the recently described T-box family, and that Tbx2 is expressed in melanocyte and melanoblast cell lines but
not in melanoblast precursor cells. Although Tbx2 and MSF each recognize the TRP-1 MSEu and MSEi motifs,
it is binding by Tbx-2, not binding by MSF, that correlates with repression. Several lines of evidence tend to
point to the brachyury-related transcription factor Tbx2 as being the repressor of TRP-1 expression: both the
MSEu and MSEi bind Tbx2, and mutations in either element that result in derepression of the TRP-1 promoter
diminish binding by Tbx2; the TRP-1 promoter, but not the tyrosinase, microphthalmia, or glyceraldehyde-
3-phosphate dehydrogenase (G3PDH) promoter, is repressed by Tbx2 in cotransfection assays; a high-affinity
consensus brachyury/Tbx2-binding site is able to constitutively repress expression of the heterologous IE110
promoter; and a low-affinity brachyury/Tbx2 binding site is able to mediate Tbx2-dependent repression of the
G3PDH promoter. Although we cannot rule out the presence of an additional, as yet unidentified factor playing
a role in the negative regulation of TRP-1 in vivo, the evidence presented here suggests that Tbx2 most likely
is the previously unidentified repressor of TRP-1 expression and as such is likely to represent the first example
of transcriptional repression by a T-box family member.
In attempting to understand how the precise temporal and
spatial pattern of gene expression necessary for the develop-
ment of an organism is achieved, consideration should be given
not only to the question of why a specific gene is expressed in
a particular cell type at any given time, but also to why it is not
expressed elsewhere or at other times. Analysis of tissue-spe-
cific promoters in many cell types has revealed that they often
contain binding sites for widely expressed transcription factors
which may act together with factors with a more restricted tis-
sue distribution. However, while these tissue-specific factors
may be present in only a very limited number of cell types, they
frequently fall into transcription factor families, members of
which have identical or highly similar DNA-binding properties.
For example, the CANNTG E-box motif is recognized by mem-
bers of the basic helix-loop-helix (bHLH) class of transcription
factors, and while some bHLH factors are clearly expressed in
a highly tissue restricted fashion, all cells contain bHLH factors
capable of recognizing the E-box motif. To enable the expres-
sion of a promoter containing an E-box element to be limited
to a specific cell type, some mechanism must operate to restrict
its expression in other cells. It seems likely that in addition to
the positive regulators of transcription which have received
much attention over recent years, sequence-specific repressors
acting to restrict expression to specific cell types may be equally
important. Indeed, lessons learned from genetic studies of
Drosophila suggest that transcriptional repressors may be as
common as activators (37).
Melanocytes afford a particularly attractive system for un-
derstanding the molecular mechanisms operating to achieve
the commitment and differentiation of a cell lineage. Melano-
cytes originate in the neural crest as a dispersed population of
melanoblasts which migrate primarily to the hair follicles and
epidermis before differentiating into mature, pigmented cells.
In addition to being responsible for skin, hair, and eye color
(41), melanocytes perform an essential function in the gener-
ation of action potentials in the inner ear (43). Moreover, in
response to UV irradiation, skin melanocytes increase the pro-
duction of the pigment melanin, which is then transferred to
the surrounding keratinocytes as protection from UV-induced
DNA damage (15). Since melanocytes are not essential for
viability, and because pigmentation is an obvious phenotype,
around 70 genes which affect the melanocyte lineage have been
identified by genetic analysis; of these 70, more than 20 have
now been cloned. The cloned genes include those whose prod-
ucts play crucial roles in melanocyte commitment, survival, or
differentiation, such as the c-Kit (31) and the endothelin B
receptors (4, 21, 36) and the transcription factors microphthal-
mia (20, 29, 46), Pax3 (2, 11), and Sox10 (34, 43), as well as
genes encoding melanogenic enzymes, such as tyrosinase and
tyrosinase-related protein 1 (TRP-1), which map to the albino
and brown loci, respectively (22, 27, 38). The isolation and
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analysis of the promoters which control expression of the ty-
rosinase and TRP-1 genes (7, 8, 9, 16, 17, 23, 26, 28, 35, 40, 49)
have provided an insight into how melanocyte-specific gene
expression is achieved. Although it was anticipated that be-
cause tyrosinase and TRP-1 are both melanogenic enzymes,
they would be subject to coordinate regulation by a shared set
of transcription factors, it is now clear that their proximal pro-
moters contain only a single common element, the M box (28).
The 11-bp M box element contains at its core a CATGTG
motif recognized by the bHLH-leucine zipper (LZ) transcrip-
tion activator microphthalmia (7, 17, 18, 48, 50), which plays an
essential role in melanocyte development. The proximal tyrosi-
nase promoter contains both the M box and a second essential
CATGTG motif located at its initiator, as well as a conserved
Sp1 element (7). By contrast, the TRP-1 promoter is consid-
erably more complex. In addition to the M box located at po-
sition 2100 with respect to the transcription initiation site, two
key melanocyte-specific elements termed the MSEu and MSEi
play critical roles in the regulation of TRP-1 expression (49).
Both the MSEu and the MSEi, located at position 2237 and
at the initiator, respectively, bind a melanocyte-specific factor
termed MSF. Mutational analysis of each element has indi-
cated that MSF plays a positive role in regulation of TRP-1
promoter activity. In contrast, both the MSEu and MSEi are
also recognized by a repressor, since mutations affecting either
of these elements result in strong up-regulation of TRP-1 pro-
moter activity. Although repressor DNA-binding activity was
not detected in cell extracts, point mutation of the MSEu and
MSEi coupled to functional analysis suggests that its DNA-
binding specificity is related to but different from that of MSF.
Clearly, establishing the identity of both MSF and the repres-
sor which play key roles in regulation of melanocyte-specific
gene expression is a major goal.
In this paper, we report that melanocyte and melanoblast
cell lines, but not melanoblast precursor cells, express the
brachyury-related transcription factor Tbx2. Although Tbx2
and MSF recognize both the TRP-1 MSEu and MSEi motifs,
it is binding by Tbx-2, not binding by MSF, that correlates with
repression.
MATERIALS AND METHODS
Cell lines and transfection assays. The mouse melanocyte cell line melan-c
was grown in RPMI 1640 with 10% fetal calf serum and 200 ng of phorbol
myristyl acetate per ml. Transfections were performed by using Lipofectamine
reagent (Life Technologies). Cells were plated at 5 3 104/ml in 5-cm-diameter
dishes 1 day before transfection. After two washes with serum-free medium, 1.7
ml of serum-free medium was added. A total of 1 mg of DNA in 100 ml of
serum-free medium was mixed with an appropriate amount of Lipofectamine in
200 ml of serum-free medium, left for 30 min at room temperature, and then
added to the cells. After 5 h at 37°C, the medium was removed and the cells were
washed once in serum-free medium before the addition of 4 ml of medium with
serum. Cells were harvested 2 days later and processed. The optimal amount of
Lipofectamine used per microgram of DNA was determined empirically for each
batch of Lipofectamine and was found to vary between 1 and 14 ml. All trans-
fections were repeated with different preparations of DNA, and pCH110 con-
taining the simian virus 40 promoter driving expression of a LacZ reporter was
used as an internal control for transfection efficiency (1 mg per transfection).
Chloramphenicol acetyltransferase (CAT) assays were performed as described
previously (49) and were quantitated by excising the spots following thin-layer
chromatography and scintillation counting. Luciferase assays were carried out as
instructed by the manufacturer of the luciferase assay reagent (Promega) and
were quantitated with a Bertholdt Microlumat LB 96Vplate luminometer. The
origin and culture of the melanocyte, melanoblast, and melanoblast precursor
cell lines used for the Northern blots have been described previously (3, 5, 6, 45).
Band shift assays. The band shift assays were performed in a final volume of
20 ml containing 20 mM HEPES (pH 7.9), 10% glycerol, and 112 mM KCl;
nuclear extracts were prepared as described previously (49). In vitro-transcribed/
translated (ITT) protein was made by using a TNT T7 Quick Coupled Tran-
scription kit as instructed by the manufacturer (Promega). Nuclear extracts or
ITT Tbx2 were preincubated at 0°C with 1 mg of poly(dIdC-dIdC) for 10 min
before the addition of 10, 50, or 250 ng of cold competitor DNA. After a further
incubation for 10 min, approximately 0.5 ng of oligonucleotide probe, labeled at
each end by filling in 59 overhangs with a Klenow fragment and the appropriate
a-32P-deoxynucleoside triphosphate, was added to the reaction for a further 20
min before loading onto a 8% polyacrylamide gel (44:1 acrylamide/bisacrylamide
ratio) and electrophoresis at 200 V for 1.5 h.
The sequences of double-stranded oligonucleotides used as probes and com-
petitors in Fig. 1, 3, and 5 are as follows: MSEi, 59-ctagaGAATTCACTGGTG
TGAGAAGGGATTAGTt-39; MSEu, 59-ctagaAAAGCTAACAGAAAATACA
AGTGTGACATTt-39; LS-MSEi, 59-ctagaGAATTCACTGGTCGACGAAGG
GATTAGTt-39; and brachyury, 59-ctagaGGGAATTTCACACCTAGGTGTGA
AATTCCCT-39. Lowercase letters indicate bases added to facilitate cloning.
Plasmids and DNA constructs. The TRP-1 and thymidine kinase (TK) pro-
moter reporter plasmids used for Fig. 1 have been described previously (49).
pAB2 contains the herpes simplex virus IE110 promoter upstream from a CAT
reporter and has also been described previously (32). Plasmid pAB2-BS was
constructed by insertion into the unique XbaI site upstream from the IE110
promoter of a double-stranded oligonucleotide containing the brachyury con-
sensus binding site (24): 59-ctagaGGGAATTTCACACCTAGGTGTGAAATT
CCCt-39. The reporter G3PDH (glyceraldehyde-3-phosphate dehydrogenase)-
CAT has been described previously (1). Plasmid G3PDH-LaBS-CAT was made
by inserting in the unique HindIII site upstream from the G3PDH promoter a
double-stranded oligonucleotide containing a low-affinity brachyury-binding site
(LaBS): agcttGGGAATTTCACACgacaacctagGTGTGAAATTCCCa.
For the luciferase assays, the TRP-1 promoter extending from 2310 to 1114
was cloned as an XbaI-HindIII fragment between the NheI and HindIII sites of
the pGL3 basic luciferase reporter vector (Promega). The microphthalmia pro-
moter between 2387 and 197 was cloned by PCR from genomic DNA by using
primers which placed SstI and HindIII sites at the 59 and 39 ends, respectively,
between the SstI and HindIII sites of the pGL3 basic luciferase reporter vector.
The tyrosinase promoter extending from 2300 to 180 was cloned as an XbaI-
XhoI fragment between the NheI and XhoI sites of the same reporter vector. The
tyrosinase and TRP-1 promoter fragments used have been described previously
(7, 28).
Antibody production. A partial Tbx2 cDNA encoding amino acids 361 to 701
was cloned into a glutathione S-transferase expression vector, and the resulting
fusion protein was expressed in Escherichia coli prior to purification and injection
into rabbits. This region of Tbx2 was chosen because it lies outside the conserved
T-box DNA-binding domain and consequently the resulting anti-Tbx2 antiserum
was unlikely to cross-react with other members of the T-box family. The anti-
Tbx2 antibody was affinity purified before use and could immunoprecipitate Tbx2
but not brachyury.
RNA extraction, RT-PCR, and Northern blot analysis. Isolation of RNA and
blotting procedures were as described (14). For the reverse transcription (RT)-
PCR isolation of the Tbx2 cDNA, total melan-a RNA was subjected to RT with
avian myeloblastosis virus reverse transcriptase (Boehringer) followed by a first-
strand cDNA synthesis (Amersham First Strand cDNA synthesis kit). The
initial identification of T-box protein was performed by PCR amplification
from melan-a cDNA with two degenerate primers, 59-agacagatctAGATA{TC}
AT{TCA}CA{IC}CCIGA{TC}{AT}{GC}ICC-39 and 59-agacagatctAGATT
{TC}TG{AG}TAIGCIGTIACIGC-39, which place BglII sites at each end of the
PCR product. PCR was performed with a reaction mixture containing 250 mM
deoxynucleotides, 2 mg of primers, 5% dimethyl sulfoxide, and 0.5 U of Taq
polymerase (Life Technologies). Cycling parameters were 1 min at 94°C, 2 min
at 40°C, and 2 min at 65°C for 36 cycles. Amplified fragments were digested with
BglII and cloned into the BamHI site of pBluescript II KS (Stratagene). After the
clones obtained by using the degenerate primers were identified by sequencing
(Amersham T7 sequencing kit), a full-length mouse Tbx2 (Tbx2FL) cDNA was




The underlined sequences correspond to a silent mutation allowing the creation
of a BglII site in the Tbx2 cDNA. The reaction amplifications were as follows: 32
cycles comprising 1 min at 94°C, 1 min at 50°C, and 2 min at 72°C. The 59 Tbx2
PCR product was cloned into pGEX-2TK digested with BamHI and EcoRI,
followed by the cloning of the 39 Tbx2 PCR product into the pGEX vector
containing the previously cloned 59 Tbx2 cDNA fragment digested with BglII-
XbaI. The Tbx2FL clone was then excised as a BamHI fragment and cloned into
pT7plink (39), an ITT vector, and into pCMV19a (50) for expression in mam-
malian cells.
RESULTS
Repression of the TRP-1 promoter in melanocytes. Previous
work (49) using transfection assays of melanoma cells has
established that the melanocyte-specific TRP-1 promoter is
primarily regulated by three specific elements: the M box, the
MSEi, and the MSEu, the latter two located at the initiator and
at position 2237, respectively (Fig. 1A). While the M box is
regulated positively by the product of the microphthalmia
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gene, the MSEi and MSEu, which each contain a conserved
GTGTGA motif, are recognized by both MSF and an unchar-
acterized repressor. Mutational analysis of the MSEu and
MSEi provided convincing evidence that the repressor was
responsible for the extremely low levels of TRP-1 promoter
activity observed in melanoma cell lines. Whether the repres-
sor was also active in nontransformed melanocytes or whether
its activity was peculiar to melanomas was not established.
Therefore, before attempting to characterize further the re-
pressor, we wished to determine whether the TRP-1 promoter
was also subject to repression mediated by the MSEu and
MSEi in melanocytes.
To determine whether the repression acting through the
MSEi was operating in untransformed melanocytes, we trans-
fected the melanocyte cell line melan-c with a TRP-1 promot-
er–CAT reporter or an identical construct (LS-MSEi) in which
four residues within the core MSEi motif had been mutated.
The LS-MSEi mutation has been shown previously to result in
around an 80-fold increase in TRP-1 promoter activity in trans-
fected melanomas (49). The result (Fig. 1B) demonstrates that
the activity of the TRP-1 promoter is significantly (around
15-fold) derepressed by the LS-MSEi mutation, indicating that
repression through this element occurs in melanocytes as well
as in melanomas. To verify that repression also was mediated
in melanocytes by the related MSEu, we made use of a sensi-
tive assay for MSEu function in which a double-MSEu element
is placed upstream from a minimal TK promoter fused to a
USF-binding site. We have used this assay previously to dem-
onstrate the repression activity mediated via the MSEu (49).
The USF-TK reporter was therefore transfected into the
melan-c melanocyte cell line either in the presence or in the
absence of wild-type (WT) MSEu or MSEu mutants (M2 and
M5) which we have previously shown to be defective for tran-
scriptional repression in melanomas. The results (Fig. 1C)
reveal that as in melanoma cells, WT MSEu, but not the M2 or
M5 mutant, confers efficient repression on the USF-TK mini-
mal promoter. Thus, the activity of the MSEu and MSEi re-
pressor is not restricted to transformed cells.
The MSEu and MSEi are bound by MSF, and previous work
using point mutations in the MSEu suggested that MSF and
the repressor bound related sequences (49). It was therefore
possible that at the MSEi, MSF participates in repression of
the TRP-1 promoter, particularly since no factor other than
MSF had been found to bind to this element. Since individual
point mutations in the MSEu GTGTGA motif severely dimin-
ished MSF binding, it was anticipated that MSF would not
recognize the LS-MSEi mutant in which four of the six bases in
the conserved GTGTGA sequence had been mutated. How-
ever, this had never previously been tested. Demonstration
that MSF could recognize the LS-MSEi would provide con-
vincing evidence that the repressor and MSF were distinct. To
test this possibility, we performed band shift assays using a
radiolabeled MSEi probe together with B16 melanoma cell
nuclear extract and tested it for MSF binding activity in com-
petition with WT MSEi, MSEu, and LS-MSEi oligonucleotides
(see Fig. 6 or Materials and Methods for full sequences of the
oligonucleotides used). The result shown in Fig. 1D demon-
strates that, surprisingly, MSF binding to the MSEi element
was competed not only by the WT MSEi and MSEu but also by
the LS-MSEi mutant. Thus, since the LS-MSEi cannot repress
transcription yet retains the ability to bind MSF, we conclude
that MSF does not act as the TRP-1 repressor. Moreover, the
fact that MSF can bind the LS-MSEi sequence suggests that at
the initiator, sequences outside the GTGTGA motif play a
significant role in recruiting MSF to the TRP-1 promoter.
Indeed, we have recently identified residues some 8 to 10 bp 39
to the MSEi which, in addition to the first two bases of the
GTGTGA sequence are essential for MSF binding (reference
49 and unpublished observations).
The brachyury-related factor Tbx2 is expressed in the me-
lanocyte lineage. The results outlined above indicate clearly
that the repression of TRP-1 is not mediated by MSF. Given
that we were unable to detect repressor DNA-binding activity
in vitro, it would not be possible to isolate the repressor by
standard biochemical means. However, one clue to the nature
of the repressor was afforded by the fact that repression at both
the MSEu and MSEi was absolutely dependent on the con-
served GTGTGA motifs. One protein known to recognize a
GTGTGA sequence is the transcription factor brachyury (19,
24, 25), which plays an essential role in mesoderm induction
during development (47). However, from what is known of the
pattern of brachyury expression during development, it would
FIG. 1. Repression of TRP-1 in melanocytes is not mediated by MSF. (A)
Schematic showing the elements required for regulation of the TRP-1 promoter.
The M box is recognized by the transcription factor microphthalmia, while the
MSEu and MSEi are targets for MSF and for negative regulation. (B) The
LS-MSEi mutation relieves repression of TRP-1 in melanocytes. The melan-c
melanocyte cell line was transfected with the indicated WT or LS-MSEi mutant
TRP-1–CAT reporters, and CAT activity was determined. (C) Repression me-
diated by the MSEu in melanocytes. Melan-c cells were transfected with the
USF-TK-CAT reporter or the indicated derivatives containing WT or mutant
MSEu elements, and CAT activity was determined 48 h posttransfection. (D)
MSF binds the WT and mutants LS-MSEi elements. A radioactive oligonucle-
otide probe containing the MSEu was used in a band shift assay with B16
melanoma cell nuclear extract, and MSF binding was competed with 10, 50, and
250 ng of unlabeled oligonucleotides containing the MSE, MSEu, or LS-MSEi.
Only the bound DNA is shown. The sequence of each oligonucleotide probe and
competitor is shown in Fig. 6.
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be surprising if it were expressed in the melanocyte lineage.
Indeed, the absence of brachyury expression in melanocytes
and melanomas was confirmed by using both RT-PCR and a
specific antibrachyury antibody (not shown). Despite this re-
sult, it was nevertheless possible that a factor sharing brachyury
DNA-binding specificity was present in melanocytes. In this
respect, recent work from Bollag et al. (10) revealed that
brachyury is encoded by a gene that belongs to a gene family
whose members possess a highly conserved DNA-binding do-
main, the T box. It was therefore possible that the TRP-1
repressor, or possibly MSF, was a member of this transcription
factor family which plays a major role in development (for
reviews of the T-box family, see references 33 and 42). To
explore this possibility, we designed degenerate PCR primers
corresponding to highly conserved regions of the T-box DNA-
binding domain. These primers were used to amplify cDNA
prepared from the melan-a melanocyte cell line. Analysis of
the PCR products by agarose gel electrophoresis revealed a
single band of around 250 bp, consistent with the size expected
to result from the amplification of a T-box-encoding sequence.
The PCR products were cloned, and 20 independent clones
were sequenced. All 20 clones analyzed contained the same
sequence, encoding the T box of the previously identified Tbx2
factor (10). Using 59 and 39 RACE (rapid amplification of
cDNA ends), we isolated a full-length cDNA which when se-
quenced corresponded exactly to that reported for mouse Tbx2
with the exception of two amino acid substitutions, Cys476 to
Gly and Arg679 to Ser, which are found in the human protein
(12). Despite repeated attempts using different primer pairs
corresponding to sequences derived from T-box factors for
which sequence information was available (Tbx-1, -3, -5, and -6
and Tbr1), no other T-box mRNAs were detected by RT-PCR
using mRNA derived from one melanoma and two different
melanocyte cell lines. Although we cannot absolutely rule out
the presence of an unidentified family member with a sequence
not compatible with any of the degenerate PCR primers tested,
it seems likely that Tbx-2 is the only member of the T-box
family present in the melanocyte lineage.
Previously, Tbx2 message has been detected by Northern
blotting in lung and kidney and at lower levels in the heart and
ovary (10). Using whole-mount hybridization in mouse em-
bryos, Chapman et al. (13) were also able to detect Tbx2 ex-
pression in a number of other tissues during development,
including the central and peripheral nervous system and the
neural retina and myotome, though expression remained re-
stricted to a subset of cell types. No expression was found in
melanocytes or melanoblasts, possibly because these cells are
present only as a dispersed population and are consequently
difficult to detect.
The presence of Tbx2 mRNA in melan-a cells raised the
possibility that Tbx2 can recognize the MSEu and MSEi. How-
ever, we were also aware that RT-PCR was an extremely sen-
sitive tool for the extraction of specific cDNAs and may some-
times result in the detection of rare messages. Therefore, we
wished to confirm the expression of Tbx2 in a range of cell
types derived from the melanocyte lineage. RNA was therefore
prepared from cell lines corresponding to different stages of
melanocyte differentiation, including melanoblast precursors,
melanoblasts, and melanocytes, and analyzed by Northern
blotting using a nonconserved region of the Tbx2 cDNA as
probe. The results (Fig. 2) revealed that Tbx2 mRNA was
present as two species, of 2.6 and 3.6 kb, which were expressed
at similar levels in three melanocyte cell lines (melan-a, melan-
m5, and melan-S1) and in four melanoblast cell lines (melb-
M5, melb-a, melb-P3, and melb-S1). Interestingly, no expres-
sion was detected in two premelanoblast cell lines, M6 and M4.
This pattern of expression is reminiscent of that of the micro-
phthalmia and c-kit genes, both of which play an essential role
in melanocyte development and which, like Tbx2, are ex-
pressed in melanocytes and melanoblasts but not in premela-
noblasts. Tbx2 was also expressed in kidney, consistent with
previous observations (10), but not in the mouse keratinocyte
cell line XB2 or in HeLa cells.
Tbx2 binds the MSEu and MSEi. As members of the T-box
family have similar DNA-binding domains, Tbx2 might be ex-
pected to recognize a sequence similar to that bound by the
transcription factor brachyury. The presence of a T-box family
member in melanocytes raised the possibility that Tbx2 either
was the repressor of TRP-1 expression or was MSF. Apart
from brachyury, which preferentially binds a palindromic GTG
TGA sequence separated by 4 bp (24), no information was
available as to the DNA-binding requirements of other mem-
bers of the T-box family. To determine whether Tbx2 was
competent to bind the MSEu sequence, ITT Tbx2 was used in
a band shift assay together with either an MSEu probe or, as a
control, a consensus palindromic brachyury binding site (Fig.
3A). Using either Tbx2FL or the C-terminally truncated form
Tbx(1-373) Tbx2 together with the brachyury probe, we de-
tected a specific complex with a mobility reflecting the size of
the translated protein and which was distinct from a low level
of nonspecific DNA-binding activity present in unprogrammed
reticulocyte lysate. A similar pattern of DNA-binding activity
was observed with the MSEu probe, although in this case sig-
nificantly more nonspecific binding arising from the reticulo-
cyte lysate was apparent. Nevertheless the results obtained
FIG. 2. The T-box transcription factor Tbx-2 is expressed in melanocytes and
melanoblasts. (A) Northern blot of 5 mg of poly(A)1 mRNA derived from the
indicated cell lines or from mouse kidney probed with either Tbx-2 or G3PDH
cDNA. Tbx2 mRNA is present as two species of approximately 2.6 and 3.6 kb.
The same blot was also probed for G3PDH message as a loading control. Note
that the HeLa lane was deliberately overloaded to illustrate that these cells do
not express Tbx2 message. M6 and M4 are premelanoblast cell lines; melan-a and
melan-M5 are mouse melanocyte cell lines; melb-M5 is a mouse melanoblast cell
line. (B) Northern blot of mRNA derived from the indicated cell lines and
probed with radiolabeled Tbx-2 cDNA. Each lane was loaded with the same
amount of RNA, as judged by staining with ethidium bromide and visualization
under UV. melan-a and melan-S1 are mouse melanocyte cell lines; melb-a,
melb-P3, and melb-S1 are mouse melanoblast cell lines; XB2 is a mouse kera-
tinocyte cell line.
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from these assays demonstrate that Tbx2 can recognize both
the palindromic, consensus brachyury-binding site as well as
the MSEu which comprises a single GTGTGA motif.
The ability of Tbx2 to recognize the MSEu element was
consistent with the possibility that Tbx2 was either MSF or the
repressor of TRP-1. To distinguish between these possibilities,
we compared the mobility of MSF derived from B16 mela-
noma cell nuclear extracts bound to an MSEu probe to the
mobility of ITT Tbx2 bound to the same probe. The result (Fig.
3B) demonstrates unequivocally that the mobilities of the two
complexes are different, strongly suggesting that Tbx2 is not
MSF. This conclusion was further substantiated by comparing
the abilities of Tbx2 and MSF to bind the LS-MSEi mutant.
We have already shown (Fig. 1) that the LS-MSEi mutation
abolishes repression at the TRP-1 promoter but fails to pre-
vent binding of MSF. In assays using an MSEu probe and
either MSF derived from B16 cells or ITT Tbx2, it is evident
that an LS-MSEi competitor binds MSF but not Tbx2 (Fig. 3C;
see also Fig. 6). Thus, binding by Tbx2, but not MSF, correlates
with repression of TRP-1 at the initiator.
Although we were able to demonstrate binding to the MSEu
and MSEi elements by using Tbx2 protein generated by ITT,
we also wished to show that Tbx2 present in cell extracts was
similarly able to bind DNA. As mentioned above, we were
consistently unable to detect any Tbx2 DNA-binding activity in
extracts from Tbx2-expressing cells. Although other explana-
tions are possible, this may be a result of a low level of Tbx2 in
the melanocyte lineage or the fact that Tbx2 is poorly extract-
able from cells. However, by transfecting B16 melanoma cells
with a Tbx2 expression vector, a specific Tbx2 DNA-binding
activity could readily be detected with a consensus brachyury-
binding site as the probe (Fig. 3D). The identity of the Tbx2-
DNA complex, which was apparent only in extracts from the
transfected cells, was confirmed by the addition to the DNA-
binding assay of a specific anti-Tbx2 antiserum which abolished
formation of the complex.
Transcription repression by Tbx2. The results described
above implicate Tbx2 in repression of the TRP-1 promoter. To
assess the ability of Tbx2 to act as a repressor in a more direct
assay, we examined whether Tbx2 was able to repress the TRP-
1 promoter in cotransfection assays. Given that the TRP-1 pro-
moter was already strongly repressed in melanocytes or mela-
nomas and is not expressed in other cell types, any additional
effect of a transfected Tbx2 expression vector might be expect-
ed to be minimal. However, when B16 melanoma cells were
transfected with a TRP-1 promoter-luciferase reporter in the
presence or absence of a Tbx2 expression vector, we were able
to demonstrate up to 20-fold repression by Tbx2 in some ex-
periments, although the more usual level of repression was in
the region of 3- to 4-fold, as shown for two independent trans-
fection experiments in Fig. 4A. The degree of repression ob-
tained could be increased in either CAT (not shown) or lucif-
erase (Fig. 4A) assays if the basal TRP-1 promoter activity was
elevated by stimulating cells with forskolin, which activates
TRP-1 promoter indirectly via transiently increasing intracel-
lular levels of the transcription factor microphthalmia (9).
As a control for specificity, we also assayed the effects of
Tbx-2 on the promoters driving expression of the melanocyte-
specific tyrosinase and microphthalmia genes. Neither promot-
er contains a Tbx2 binding site and as such would not expect to
be repressed by expression of Tbx2 in a cotransfection assay.
Consistent with this, no repression of either promoter was
observed in the presence of a Tbx2 expression vector (Fig. 4B
and C). Thus, repression of TRP-1 by Tbx2 is promoter spe-
cific.
While it was evident that Tbx2 could specifically repress the
TRP-1 promoter, it was also possible that repression was de-
pendent on the specific arrangement of elements within the
TRP-1 promoter. To demonstrate that Tbx2 could also act
independently of promoter context, we also examined whether
Tbx2 could repress a non-melanocyte-specific promoter when
linked to a consensus brachyury-binding site. We initially tried
the herpes simplex virus IE110 promoter, which was strongly
FIG. 3. Tbx2 can bind the MSEu and MSEi and is distinct from MSF. (A)
Band shift assay using a radiolabeled brachyury-binding site or the MSEu as the
probe together with either unprogrammed reticulocyte lysate, ITT Tbx2FL, or
the C-terminal truncation Tbx2(1-373). Only the bound DNA is shown. The
asterisk indicates the position of a complex originating in the unprogrammed
reticulocyte lysate and which has a mobility similar to that of MSF. (B) Band shift
assay as in panel A, using the MSEu probe and either B16 nuclear extract or ITT
Tbx2. The relative positions of the MSF- and Tbx2-containing complexes are
indicated. (C) As for panel B but with 50 ng of the indicated LS-MSEi compet-
itor where indicated. (D) Band shift assay using B16 extract derived from un-
transfected cells (control) or cells transfected with a Tbx2 expression vector,
together with a brachyury consensus binding site as a probe. The DNA-binding
reaction was performed in the presence or absence of a polyclonal anti-Tbx2
antiserum as indicated.
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expressed following transfection of melan-c cells. However,
even in the absence of any cotransfected Tbx2 expression vec-
tor, the presence of a brachyury/Tbx2 consensus binding site
upstream from the IE110 promoter resulted in efficient repres-
sion (Fig. 5A). This result illustrated that in melanocytes, the
brachyury/Tbx2 consensus binding sequence could act as a
strong negative regulatory element and that repression was not
peculiar to the MSEu and MSEi elements; in addition, we
demonstrated for the first time that the repression mediated by
a Tbx-2-binding site was not confined to melanocyte-specific
promoters. Nevertheless, the fact that the IE110-CAT reporter
was so severely repressed by the brachyury/Tbx2-binding se-
quence meant that this particular reporter could not readily be
used to determine whether Tbx2 expression directed repres-
sion in a cotransfection assay. In an attempt to circumvent this
problem, we considered using a low-affinity brachyury-binding
site. Previously, Kispert et al. (25) demonstrated that com-
pared to the high-affinity consensus sequence, brachyury was
able to activate transcription around fivefold less well from an
element in which the two half sites are separated by 9 bp. We
therefore designed a similar site (LaBS; Fig. 5D) in which the
spacing between the two half sites was increased to 10 bp. Us-
ing ITT brachyury in a DNA-binding band shift assay together
with the high-affinity consensus site as a probe, we competed
brachyury for binding with either the high-affinity site or the
altered spacing mutant. The result (Fig. 5B) revealed that as
expected, brachyury could not recognize this altered spacing
mutant. Similarly, brachyury was unable to recognize either the
MSEu or the MSEi from the TRP-1 promoter, consistent with
previous reports that DNA binding by brachyury requires two
half sites (24).
Since we already knew that Tbx2 was able to bind the single
half sites present in the MSEu and MSEi, we anticipated that
it would also recognize the low-affinity altered spacing mutant,
FIG. 4. Specific repression of the TRP-1 promoter by Tbx2. B16 melanoma
cells were transfected with the indicated TRP-1 (A), tyrosinase (Tyros) (B), or
microphthalmia (Mi) (C) promoter-luciferase (Luc) reporters either alone or
together with the Tbx2 expression vector. The open and filled columns represent
the results from two independent transfection experiments. Forskolin was added
at 20 mM to the indicated transfection assay. Luciferase activity was determined
48 h posttransfection.
FIG. 5. Transcriptional repression by Tbx2 in melanocytes. (A) Schematic
showing the structure of the herpes simplex virus IE110 promoter (in pAB2) and
the consensus brachyury site (BS). (B) Brachyury does not bind the LaBS, the
MSEu, or the MSEi, as determined by band shift assay using ITT brachyury
together with the consensus brachyury probe and 10, 50, or 250 ng of the
indicated consensus BS, LaBS, and MSEu, and MSEi competitors. (C) Tbx2
binds the consensus brachyury site around 5-fold better than the LaBS and
around 15-fold better than the MSEu, as determined by band shift assay using
ITT Tbx2 together with the consensus brachyury probe and 10, 50, or 250 ng of
the consensus (BS) or low-affinity (LaBS) brachyury site or MSEu as the com-
petitor. Only the bound DNA is shown. The full sequences of the BS and LaBS
sites are shown in panels A and D, respectively. (D) Transcriptional repression
by Tbx2. The indicated G3PDH-CAT or G3PDH.LaBS-CAT reporters were
transfected into the melanocyte cell line melan-c either alone or together with a
Tbx2 expression vector, and CAT activity was determined 48 h posttransfection.
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though less well than the full consensus sequence. To verify
that Tbx2 would indeed recognize the low-affinity binding site
less well than the consensus sequence, we used the consensus
site as a probe in a band shift assay together with ITT Tbx2 and
performed competition for Tbx2 binding, using either the high-
affinity consensus sequence, the LaBS, in which the spacing
between the two half sites had been extended to 10 bp, or the
MSEu. The result (Fig. 5C) showed that as expected, Tbx2
bound the LaBS around fivefold less well than the consensus
sequence. Nevertheless Tbx2 binding to the LaBS was still
more efficient than to the MSEu, illustrating that while Tbx2
can bind the single half sites present in the MSEu and MSEi,
binding is significantly enhanced by the presence of two half
sites.
On the basis of these results, we constructed a CAT reporter
comprising the highly active G3PDH promoter linked to the
brachyury/Tbx2 LaBS in which the spacing between the two
half sites had been increased from 4 to 10 bp. In transfected
melan-c cells, expression of the G3PDH promoter was re-
pressed no more than 20% in the presence of the modified
brachyury/Tbx2-binding site (Fig. 5D). In contrast, expression
of the G3PDH promoter linked to the modified brachyury/
Tbx2-binding site (G3PDH.LaBS) was repressed around eight-
fold by Tbx2 in this assay, while the G3PDH promoter itself
was barely affected. We conclude from these experiments that
expression of Tbx2 results in transcriptional repression from
promoters containing appropriate Tbx2 recognition sequences.
DNA-binding specificity of Tbx2. Although Tbx2 was able to
bind the MSEu and MSEi from the TRP-1 promoter, and each
of these elements contained a conserved GTGTGA motif, the
precise requirements for DNA binding by Tbx2 were not ap-
parent. Understanding how Tbx2 recognized DNA would be of
use in identifying alternative binding sites for this factor in
other promoters and would in addition yield insight into DNA
recognition by the T-box family in general. DNA binding by
Tbx2 was therefore assessed by using the MSEu probe and an
extensive series of competitors bearing modifications to the
MSEu or MSEi sequence. The sequences of the probes and
competitors used are shown in Fig. 6A; results of the DNA-
binding assays with the indicated competitors are summarized
in Fig. 6B and displayed in Fig. 6C. We initially concentrated
on introducing mutations in the conserved GTGTGA motifs.
Thus, as shown above, Tbx2 was able to bind both the MSEu
and MSEi with around the same efficiency but was not able to
bind the LS-MSEi mutant. Tbx2 also failed to bind an MSEu
in which either the left (mutant M1) or right (M2) half site of
the GTGTGA motif was mutated. Similarly, no competition
was observed in assays using either the M3 or M4 mutant in
which the two 59 flanking bases in addition to residues 1 or
1 and 5, respectively, within the GTGTGA sequence were
affected. Since the M1 to M4 mutations affected multiple base
pairs, we also wished to assess the impact of single base changes
within the conserved sequence. The results showed that G-to-T
or A-to-C transversions at positions 1, 3, 4, and 6 (pm1, pm3,
pm4, and pm6) all severely inhibit binding by Tbx2. In contrast,
transversion mutations at positions 2 and 5 (pm2 and pm5) do
not affect binding more than two- to threefold. Thus, Tbx2 may
be able to recognize not only a GTGTGA motif but also the
sequence GGGTGA or GTGTTA.
We next examined whether bases flanking the 39 side of the
core GTGTGA sequence were important for recognition by
Tbx2 by using mutants pm7 and pm8 as competitors. We ob-
served no effect of pm7 and only a marginal effect of pm8.
Thus, bases to the 39 side of the MSEu appear to play little role
in binding Tbx2.
In addition to examining the sequence requirements for
DNA binding by Tbx2, we wondered whether the specific con-
tacts between Tbx2 and its target sequence occurred in the
major or minor groove. To address this question, we made use
of oligonucleotide competitors bearing modifications which
affected specific aspects of the major groove. Thus, the three G
residues at positions 1, 3, and 5 within the GTGTGA motif of
the MSEu.mG competitor were modified by the addition of a
methyl group which would extend into the major groove and
inhibit DNA binding by any protein making intimate major
groove contacts. Consistent with Tbx2 binding in the major
groove, the MSEu.mG competitor failed to bind Tbx2. How-
ever, surprisingly, the MSEu.mC oligonucleotide, in which the
major groove is modified by the presence of a methyl group on
the C residues at positions 3 and 5 on the bottom strand, bound
Tbx2 as well as the WT MSEu. These data suggest that in
binding the MSEu, Tbx2 makes asymmetric contacts within the
major groove since methylation of G residues on the top strand
inhibits binding whereas methylation of the C residues on the
bottom strand does not. The importance of the major groove
contacts was confirmed by using the MSEu.CI oligonucleotide,
in which each T residue within the GTGTGA motif is substi-
tuted by C and each A is changed to inosine. In this mutant, the
minor groove would provide an identical interface to the WT
MSEu, while the major groove would be significantly differ-
ent. Consistent with Tbx2 making major groove contacts, the
MSEu.CI mutant failed to bind Tbx2. Finally, an additional
competitor (MSEu.mC2) in which the 39 C residue on the top
strand was methylated, bound Tbx2 efficiently, confirming the
results using the pm7 and pm8 mutants which showed little
effect of mutating bases 39 to the conserved GTGTGA ele-
ment.
DISCUSSION
Previously we proposed a model in which the TRP-1 promot-
er was regulated positively by microphthalmia and MSF and
negatively by an unidentified repressor (49). We suggested
further that MSF and the repressor might act antagonistically
through the MSEu and MSEi elements and that the repression
observed in melanoma cells might reflect the fact that these
cells were transformed. In this report, we have demonstrated
that repression of the TRP-1 promoter occurs not only in
melanoma cells but also in the melanocyte cell line melan-c.
The repression of the TRP-1 promoter can be overcome by
mutation of the MSEu and MSEi, and although both elements
can bind MSF, it is clear, most convincingly from assays using
the LS-MSEi mutation, that MSF is not the repressor of TRP-1
expression. In contrast, several lines of evidence tend to point
to the brachyury-related transcription factor Tbx2 as being the
repressor of TRP-1 expression: both the MSEu and the MSEi
bind Tbx2, and mutations in either element that result in de-
repression of the TRP-1 promoter diminish binding by Tbx2;
the TRP-1 promoter, but not the tyrosinase, microphthalmia,
or G3PDH promoter, was repressed by Tbx2 in cotransfec-
tion assays; a high-affinity consensus brachyury/Tbx2-binding
site was able to repress expression of the herpes simplex virus
IE110 promoter; and a low-affinity brachyury/Tbx2-binding site
was able to mediate Tbx2-dependent repression of the strong
G3PDH promoter. Although we cannot absolutely rule out the
presence of an additional, as yet unidentified factor playing a
role in the negative regulation of TRP-1 in vivo, the evidence
presented here suggests that Tbx2 is the previously unidenti-
fied repressor of TRP-1 expression and as such is likely to
represent the first example of transcriptional repression by a
T-box family member.
In the melanocyte lineage, Tbx2 mRNA is expressed in both
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melanoblast and melanocyte cell lines but not in melanoblast
precursors. What controls the expression pattern of Tbx2 in
development is not known, though it is intriguing that the Tbx2
promoter contains a potential microphthalmia-binding site (our
unpublished observations). In light of this observation, it is
possible that the onset of microphthalmia expression upon
commitment to the melanocyte lineage in turn results in acti-
vation of Tbx2 expression, while in other cell types Tbx2 would
be regulated by other tissue-specific bHLH or bHLH-LZ fac-
tors. While this is an attractive possibility, it is at present no
more than speculation, as is the reason why the TRP-1 pro-
moter may be controlled by Tbx2. Although melanoblasts are
nonpigmented, they nevertheless express TRP-1 mRNA (4a).
Since Tbx2 is expressed in both melanoblast and melanocyte
cell lines, it might be expected that TRP-1 would be repressed
in both cell types. However, the presence of Tbx2 in a cell does
not necessarily mean that Tbx2 will act constitutively as a
repressor of transcription. Indeed, we have obtained prelimi-
nary evidence that Tbx2 expression is regulated by cellular
stress and that Tbx2 may be regulated by a variety of signal
FIG. 6. DNA-binding specificity of Tbx2. A series of WT and mutant oligonucleotides based on the MSEu or MSEi was used in band shift assays (C) together with
ITT Tbx2. The probes and competitors are indicated. Competitors were used at 10, 50, and 250 ng. The sequences or the probes and competitors are shown in panel
A along with the full sequence of the parental MSEu or MSEi oligonucleotide. The derivatives used in the competition assays are identical except for the indicated
residues shown in lowercase. mG, methylated G residue; mC, methylated C residue; I, inosine. For ease of reference, the bases within the GTGTGA motif are numbered
1 to 6. (B) Summary of the binding assays shown in panel C. Only the bound DNA is shown.
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transduction pathways which may act to modulate its function
(our unpublished observations). Thus, the regulation of TRP-1
expression by Tbx2 may be dependent on environmental cues.
This may be especially important in vivo during the migration
of the melanoblast from the neural crest and its subsequent
differentiation in the hair follicles and epidermis. The consti-
tutive repression of TRP-1 by Tbx2 observed in tissue culture
should therefore be taken only as indicative that at some stage
in the development or differentiation of the melanocyte lin-
eage, Tbx2 is likely to modulate the activity of the TRP-1
promoter in vivo.
Although here we have provided evidence for Tbx2-medi-
ated repression of the TRP-1 promoter, given that Tbx2 ex-
pression appears in melanoblasts, Tbx2 may also play a role in
the commitment to or maintenance of the melanocyte lineage.
The identification of additional Tbx2 target genes will be es-
sential if the function of Tbx2 expression is to be understood.
Our analysis of the DNA-binding specificity of Tbx2 suggests
that it may be able to recognize not only the GTGTGA motifs
present in the MSEu and MSEi but also GGGTGA or GTG
TTA. Analysis of the binding specificity of brachyury by using
binding site selection (24) revealed that like Tbx2, brachyury
can recognize the GTGTTA sequence in addition to GTGT
GA. However, in the selection assay, no GGGTGA sequence
bound by brachyury was selected, which may mean that this
sequence represents a relatively low affinity binding site for
brachyury or possibly that Tbx2 and Brachyury have related
but distinct DNA-binding specificities. The fact that brachyury
and Tbx2 bind DNA in distinct fashions is highlighted by the
fact that while brachyury binding requires two half sites, Tbx2
can bind, although with reduced affinity, to the single half sites
present in the MSEu and MSEi as well as the LaBS created by
increasing the spacing between the two half sites to 10 bp.
Recently, the crystal structure of the brachyury DNA-bind-
ing domain bound to DNA was determined (30). Given that
the Tbx2 DNA-binding domain has a high degree of homology
with that of brachyury, it is likely that the structure of the Tbx2
DNA-binding domain is similar to that of Brachyury. The
brachyury T-box–DNA cocrystal structure revealed three ma-
jor features of interest. First, the sequence used, an inverted
repeat of an AGGTGTGA motif, exhibits a substantially wid-
ened minor groove but no DNA bending; second, bp 3 and 5
within the half sites used for the crystallization are important
specificity determinants, while bp 6 and 7 are less important;
and third, the contacts made with the DNA occur in both the
minor and major grooves. Our analysis of Tbx2-binding spec-
ificity is broadly in agreement with this. Thus, mutations such
as pm1 and pm3 (Fig. 6) which affect the equivalent of bp 3 and
5 of the DNA in the crystal structure abolish Tbx2 binding,
while mutant pm5, which affects the equivalent of bp 7, has a
relatively minor impact. Moreover, the main contact point for
brachyury in the major groove is a single G residue (bp 5 in the
crystal structure). Thus, methylation of the G residues within
the binding site should severely affect binding of Tbx2, while
methylation of the C residues on the opposite strand should
have little effect, exactly as observed (Fig. 6). Thus, the data
from our DNA-binding studies and the structure of the
brachyury T-box–DNA complex are also in agreement on this
point. Nonetheless, some differences are apparent. Notably,
the results from the crystal structure suggest that the close
contact between Phe215 of brachyury and the T/A base pair at
position 4 will not tolerate its substitution. Yet while that
specific Phe residue is conserved in Tbx2, mutation of that T/A
base pair to G/C (pm2) fails to abolish binding by Tbx2. It is
therefore possible that the protein-DNA contacts for the T-box
family are different on different target sites or that residues
which are not conserved between the brachyury and Tbx2
DNA-binding domains influence DNA-binding specificity.
Whatever the precise nature of the relative DNA-binding
abilities of Tbx2 and brachyury, the analysis of the Tbx2-bind-
ing specificity and the fact that the consensus brachyury-bind-
ing site used for the band shift assays binds Tbx2 efficiently
strongly suggest that at least some brachyury target genes may
be regulated by Tbx2. What these targets may be is currently
unclear, though embryonic fibroblast growth factor is one pos-
sibility. Moreover, brachyury has been reported to be a tran-
scription activator, while in melanocytes a brachyury-binding
site acts as a strong repression element and Tbx2 appears to
act as a repressor. Thus, different members of the T-box family
may have opposing roles in transcription regulation which may
be particularly significant in cells where more than one T-box
family member is present. However, while brachyury can acti-
vate transcription and Tbx2 can repress, does this inevitably
mean that these factors have immutably defined but opposing
roles in transcription regulation? Not necessarily. Deletion
analysis of brachyury suggested that it may contain both acti-
vation and repression domains (25). Although we have yet to
examine the requirements within Tbx2 for transcription regu-
lation, it is possible that brachyury and Tbx2 each play roles as
both activators and repressors, depending on their responsive-
ness to different signal transduction pathways or the context
and arrangement of their binding sites within a target promot-
er. Since the repertoire of signaling pathways which may be
active is likely to differ in different cell types, the role of indi-
vidual members of the T-box family may vary between tissues
or during development. Future work will be directed toward
exploring these issues.
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